Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. - Wikidata - awgldk - TriplyDB

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

http://www.wikidata.org/entity/Q42233112

about

Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress Suvorexant: a promising, novel treatment for insomnia Unmet needs of patients with narcolepsy: perspectives on emerging treatment options A Framework for Quantitative Modeling of Neural Circuits Involved in Sleep-to-Wake Transition Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man.Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators A physiologically based model of orexinergic stabilization of sleep and wake Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials.Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data.Advances in the management of insomnia Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.Suvorexant, a dual orexin receptor antagonist for the management of insomnia.Suvorexant.Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea.On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers The hypocretins and the reward function: what have we learned so far?Genes and primary headaches: discovering new potential therapeutic targets.On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.Orexin receptor antagonists as therapeutic agents for insomnia Discovery and development of orexin receptor antagonists as therapeutics for insomnia.Sites of action of sleep and wake drugs: insights from model organisms.Suvorexant: The first orexin receptor antagonist to treat insomnia.Kinetic properties of "dual" orexin receptor antagonists at OX1R and OX2R orexin receptors.Distinct effects of IPSU and suvorexant on mouse sleep architecture.Suvorexant-Induced Dream Enactment Behavior in Parkinson Disease: A Case Report.Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.The Black Book of Psychotropic Dosing and Monitoring.DEC2 modulates orexin expression and regulates sleep.

P2860

Q26740978-E0FA86D7-B077-4D8F-95AE-FA382D3078B6 Q26751277-DB1F8A34-FDFB-4776-8D23-8E900600DC01 Q26767259-6BBDF2F7-5EBC-4967-A13B-D8A552CB6402 Q26827736-C4736401-5403-4101-94D5-600C610DF8D7 Q27016617-42A5CFFE-D23C-49F1-8EE6-7EBCD2DF6D5D Q27347707-C9594A93-9235-4C92-BDE1-32D166325938 Q30375507-E21F5EE5-7831-4379-B5DD-36DD9F620598 Q30423240-0F3B88DA-BF0A-4903-82BB-B0AE7993280D Q30441208-4407AA41-BEB0-47F3-8FFC-F2EE3C352DFB Q31113697-A8A13131-F634-4481-9093-0559ADA4BBFE Q31171354-437964CB-FA7C-4BE9-9D36-1D1A5198DF78 Q33720437-B483AFDE-B0A2-469E-80A4-90C9D8F59498 Q34238302-4CC36A02-D25A-4555-B22F-521CD39A6CF6 Q34661456-61CEDFB4-96A4-4027-AFA2-A425E12577A3 Q35063116-CE5FE558-A6F3-4E78-88FB-1FBF73434746 Q36432739-232CCF83-793C-4B35-BCA0-E189B27B40B5 Q36744112-4B5208D7-DB6E-4D02-9804-8656EF1CF3D8 Q36923729-B134300D-0913-49EE-A90F-B26BE8418FFD Q37027988-EB2180A0-17BC-45C1-BDD9-3BD36093AA44 Q37184429-8825BBDA-6429-4F0E-87E3-237E740F69C3 Q37413138-29E9AE9A-9147-440F-8913-465F3C1C3113 Q37522859-5D9738BD-A020-4FB8-9E8B-988999C5BB0D Q38109329-C97A8B66-A145-40BD-8988-D7D51403EFC1 Q40250481-9A317D29-E145-41FA-9555-42AF1CFE95B1 Q41998350-69AEBEB8-74C5-4491-BAEF-C776BDB05520 Q42825760-6AB08732-FBDC-4CCA-B399-1BC9CADFA39A Q43236304-C9D623EF-40D2-4CFC-9CEC-6DDDEAB3C0DC Q47590020-E34594AF-2BF9-47DA-8FF6-D8BD7CF42DEE Q47642128-44BD5076-487B-4CB2-ACE8-9A22253993FF Q53435826-0AAF02E0-FB55-47C0-BD67-848B9C04ECC9

P2860

Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men.

http://www.wikidata.org/entity/Q42233112

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Effects of suvorexant, an orex ...... olysomnography in healthy men.

@en

Effects of suvorexant, an orex ...... olysomnography in healthy men.

@nl

type

label

Effects of suvorexant, an orex ...... olysomnography in healthy men.

@en

Effects of suvorexant, an orex ...... olysomnography in healthy men.

@nl

prefLabel

Effects of suvorexant, an orex ...... olysomnography in healthy men.

@en

Effects of suvorexant, an orex ...... olysomnography in healthy men.

@nl

P1433

Q42233112-D9FDEB90-3F57-438C-A598-4954A3B683E5

P1476

Q42233112-7371BFC3-E397-4183-A40E-0C37321F0780

P2093

Q42233112-1DD9E545-B312-4FEB-8EF3-5D5971337A10

Q42233112-28F226DA-3B19-4394-83AB-D91BA6D79154

Q42233112-2EBA8F95-CE59-4B2F-9628-3D78D4CBB3A8

Q42233112-43A9C8EE-C102-4666-AA31-4D036657061F

Q42233112-4AF71D00-87FC-4647-B674-632DB6DA7737

Q42233112-62B59270-8B7C-4278-A505-469F3BED9709

Q42233112-7BBDF34B-7D00-4209-A5CC-6737506629C0

Q42233112-88D1A71D-5025-4D62-ABBC-BE73BF71A96F

Q42233112-971B84E5-3A4F-4838-B6D9-7785313B43CA

Q42233112-98EE8ECF-64D2-4BA5-8550-39F4E22A7B9F

P2860

Q42233112-07C30508-AADA-4080-ADFD-C0F2F5DCAC84

Q42233112-0A277883-0BC2-4B91-B143-C3AF58530D5B

Q42233112-165CF814-1E9B-4355-8725-E1749E202718

Q42233112-1F630321-78C5-4FEC-91F5-9A64A5179823

Q42233112-20597D2D-1F86-4866-9D86-D7B1632A516A

Q42233112-3254AC2D-6BDC-4DD0-A118-30C045954517

Q42233112-59310F47-58FF-410C-AEB7-55337A83FB3C

Q42233112-638839FD-A2E7-4949-8E5C-BC40DF3B7D85

Q42233112-65AEEBA2-000D-44AF-9A7B-E3499F93CB02

Q42233112-6C08084C-532A-4646-9113-9ED0581505D9

P304

Q42233112-DE1A2331-5275-4421-99B7-649E0397C0DB

P31

Q42233112-5C8E678D-7BCF-48C4-BD19-63A954715559

P356

Q42233112-04259DC2-AE98-4C75-9A9E-46114001F101

P433

Q42233112-78885CD6-0985-4F78-8FAE-3565FF9BAABE

P478

Q42233112-D3AC2932-5188-4FB2-80A9-B5743CCAB397

P577

Q42233112-AE98EFBC-2CBE-404C-BFB1-EBEE2688AD41

P5875

Q42233112-643D85EF-ABD6-42A4-A2BC-83F8FB2A1469

P698

Q42233112-5988547F-0185-41AD-AC76-EF672E0D3751

P921

Q42233112-C557B3FF-7AA9-4FB0-AB39-7FDDC483160C

P932

Q42233112-B8F1D83A-AE8C-4208-8669-D08CEC39E642

P356

P1433

P1476

Effects of suvorexant, an orex ...... olysomnography in healthy men.

@en

P2093

Christopher Lines

http://www.w3.org/2001/XMLSchema#string

Darren Wilbraham

http://www.w3.org/2001/XMLSchema#string

Eric Mangin

http://www.w3.org/2001/XMLSchema#string

Gail M Murphy

http://www.w3.org/2001/XMLSchema#string

Hong Sun

http://www.w3.org/2001/XMLSchema#string

Jeffrey Chodakewitz

http://www.w3.org/2001/XMLSchema#string

Junshui Ma

http://www.w3.org/2001/XMLSchema#string

Ka Lai Yee

http://www.w3.org/2001/XMLSchema#string

Laura Rosen

http://www.w3.org/2001/XMLSchema#string

Nicole Calder

http://www.w3.org/2001/XMLSchema#string

P2860

The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity

Orexin receptors: pharmacology and therapeutic opportunities

Proposed supplements and amendments to 'A Manual of Standardized Terminology, Techniques and Scoring System for Sleep Stages of Human Subjects', the Rechtschaffen & Kales (1968) standard

Neurons containing hypocretin (orexin) project to multiple neuronal systems

Orexin A activates locus coeruleus cell firing and increases arousal in the rat.

Effects of hypnotics on the sleep EEG of healthy young adults: new data and psychopharmacologic implications.

The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders.

Effect of zopiclone and midazolam on sleep and EEG spectra in a phase-advanced sleep schedule.

The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness.

Promotion of sleep by targeting the orexin system in rats, dogs and humans.

P304

259-267

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5665/SLEEP.2386

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235392961

http://www.w3.org/2001/XMLSchema#string

P698

23372274

http://www.w3.org/2001/XMLSchema#string

P921

P932

3542986

http://www.w3.org/2001/XMLSchema#string